Neoadjuvant Therapy

Preoperative neoadjuvant chemotherapy can reduce tumour burden, improve surgical outcomes, and improve survival in advanced ovarian cancer or poor performance status. A propensity score-matched analysis suggested improved overall survival for resectable high-risk ICC patients receiving neoadjuvant chemotherapy. Eligible patients must have received at least three 21-day cycles of paclitaxel plus carboplatin before surgery. In NEO-ERA-01, adjuvant capecitabine plus adebrelimab continues for six months after resection. Neoadjuvant therapy aims to eliminate micrometastases, downstage tumors, improve R0 resection probability, and reduce postoperative recurrence. The protocol assumes ovarian cancer patients after neoadjuvant chemotherapy may have lower pain thresholds and need higher opioid doses for adequate analgesia. Neoadjuvant chemotherapy may alter pain sensitivity by reducing opioid receptor function and inducing calcium overload. Neoadjuvant chemotherapy can complicate anaesthetic and analgesic care by altering organ function, nervous system sensitivity, pain thresholds, and drug metabolism. Neoadjuvant therapy is indicated for technically resectable tumors that carry high-risk…